# BridgeBio Pharma, Inc.: Form 8-K, filed May 4, 2023

- Company: [BridgeBio Pharma, Inc.](/companies/bbio.md) (CIK 1743881)
- Form: 8-K
- Filed: 2023-05-04
- Accepted by EDGAR: May 4, 2023, 17:18 ET
- Period: 2023-05-03
- Accession: 0001193125-23-136095
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1743881/000119312523136095/d336282d8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1743881/000119312523136095/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 1.02: Termination of a material agreement
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1743881/000119312523136095/d336282d8k.htm

Filed May 4, 2023.
Source: SEC EDGAR, the filing index for accession 0001193125-23-136095. Last ingested by Listed: Nov 12, 2026, 17:56 ET. No prices; not investment advice.